Literature DB >> 31082349

Endophthalmitis Rates and Clinical Outcomes Following Penetrating and Endothelial Keratoplasty.

Durga S Borkar1, Turner D Wibbelsman1, Preema M Buch2, Sara B Rapuano2, Anthony Obeid1, Allen C Ho1, Jason Hsu1, Carl D Regillo1, Brandon D Ayres2, Kristin M Hammersmith2, Parveen K Nagra2, Irving M Raber2, Christopher J Rapuano2, Zeba A Syed3.   

Abstract

PURPOSE: To evaluate endophthalmitis rates after penetrating keratoplasty (PK) and endothelial keratoplasty (EK) and to compare clinical outcomes.
DESIGN: Retrospective cohort study.
METHODS: The medical and billing records of several large academic private practices in Philadelphia, PA were electronically queried for all surgical visits during which a PK or EK was performed between April 1, 2012 and August 31, 2018. Demographic information and transplant characteristics were recorded for each patient and office visit. An additional query was performed to identify all cases of endophthalmitis based on diagnosis and procedure billing codes. Charts of patients with endophthalmitis were individually reviewed, and information was collected on triggering factors, clinical evaluation at presentation, management, culture data, visual outcomes, and graft survival rates. The main outcome measure was incidence of presumed infectious endophthalmitis following PK or EK.
RESULTS: During the study period, 1676 PKs and 2292 EKs for 3069 patients were performed. The mean age of patients in this transplant cohort was 66.4 (± 17.5) years and 54.6% of patients were women. Sixteen cases of endophthalmitis occurred during the study period; 12 cases of endophthalmitis occurred after PK and 4 cases occurred after EK. The rate of endophthalmitis after EK (4 of 2292; 0.2%) was significantly lower than that after PK (12 of 1676; 0.7%) (P = .01). In addition, the odds of developing endophthalmitis after PK or EK performed in conjunction with anterior vitrectomy were significantly higher than after either PK or EK alone (odds ratio 8.66; 95% confidence interval 2.98-25.18; P < .001). Visual acuity outcomes were poorer after PK-related endophthalmitis than EK-associated cases (P = .01). The rate of graft failure at final follow-up was significantly higher in post-PK endophthalmitis (P = .02).
CONCLUSIONS: In this large cohort of patients undergoing either PK or EK, rates of endophthalmitis were low for both procedures and significantly lower for EK compared with PK. Eyes with endophthalmitis after PK had poorer visual acuity outcomes and graft prognosis compared with those with endophthalmitis after EK.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31082349     DOI: 10.1016/j.ajo.2019.05.004

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  [Treatment of postoperative endophthalmitis : Operate or only inject?]

Authors:  L Mautone; C Skevas; M S Spitzer
Journal:  Ophthalmologe       Date:  2021-02-10       Impact factor: 1.059

2.  Need for a standardized antibiotic prophylaxis in keratoplasty.

Authors:  María García Lorente; Ismael Molina González; Carlos Rocha de Lossada; Francisco Zamorano Martín; Javier García-Montesinos; Vito Romano; Marina Rodríguez Calvo de Mora
Journal:  Eye (Lond)       Date:  2020-11-24       Impact factor: 3.775

3.  Cluster of Symptomatic Graft-to-Host Transmission of Herpes Simplex Virus Type 1 in an Endothelial Keratoplasty Setting.

Authors:  José Afonso Guerra-Assunção; Jeroen J A van Kampen; Sunando Roy; Lies Remeijer; Judy Breuer; Georges M G M Verjans
Journal:  Ophthalmol Sci       Date:  2021-08-12

4.  Acute endophthalmitis after penetrating and endothelial keratoplasty at a tertiary eye care center over a 13-year period.

Authors:  Shilpa Das; Muralidhar Ramappa; Ashik Mohamed; Sunita Chaurasia; Savitri Sharma; Taraprasad Das
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

5.  Antifungal Efficacy and Safety of Cycloheximide as a Supplement in Optisol-GS.

Authors:  Melissa Dal Pizzol; Eduarda Correa Freitas; Claudete Locatelli; Felipe Guareze; Paula Reginatto; Gabriella Machado; Alexandre Fuentefria; Diane Marinho
Journal:  Drug Des Devel Ther       Date:  2021-05-18       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.